July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
A novel antisense oligonucleotide approach to treat eye diseases by increasing target gene expression
Author Affiliations & Notes
  • Jacob Kach
    Stoke Therapeutics, Bedford, Massachusetts, United States
  • Kian Huat Lim
    Stoke Therapeutics, Bedford, Massachusetts, United States
  • Sebastien Weyn-Vanhentenryck
    Stoke Therapeutics, Bedford, Massachusetts, United States
  • Aditya Venkatesh
    Stoke Therapeutics, Bedford, Massachusetts, United States
  • Isabel Aznarez
    Stoke Therapeutics, Bedford, Massachusetts, United States
  • Gene Liau
    Stoke Therapeutics, Bedford, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Jacob Kach, Stoke Therapeutics (E), Stoke Therapeutics (I); Kian Huat Lim, Stoke Therapeutics (E), Stoke Therapeutics (I); Sebastien Weyn-Vanhentenryck, Stoke Therapeutics (E), Stoke Therapeutics (I); Aditya Venkatesh, Stoke Therapeutics (E), Stoke Therapeutics (I); Isabel Aznarez, CA 2963288 (P), CA 3005128 (P), Stoke Therapeutics (E), Stoke Therapeutics (I); Gene Liau, Stoke Therapeutics (E), Stoke Therapeutics (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3423. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jacob Kach, Kian Huat Lim, Sebastien Weyn-Vanhentenryck, Aditya Venkatesh, Isabel Aznarez, Gene Liau; A novel antisense oligonucleotide approach to treat eye diseases by increasing target gene expression. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3423.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Stoke Therapeutics is developing medicines to treat diseases by leveraging antisense oligonucleotides (ASOs) to increase gene expression. Stoke’s approach, TANGO (Targeted Augmentation of Nuclear Gene Output) exploits naturally-occurring non-productive splicing events identified using a proprietary bioinformatics pipeline to increase target protein levels via splicing modulation.Diseases of the eye are well suited to TANGO due to ASO capacity to reach target cells in the back of the eye. We are exploring a non-productive splicing event in CD274 to increase expression of PD-L1 to treat autoimmune diseases, such as uveitis. In addition to TANGO, ASOs can also be used to switch gene isoforms. For example, we can switch from the membrane-bound isoform of vascular endothelial growth factor (mbVEGF), which promotes pathologic neovascularization in age related macular degeneration, to the soluble isoform (sVEGF), which inhibits neovascularization. Finally, we evaluated the durability of uniformly modified 2’-O-methoxyethyl (MOE) ASO activity in the mouse retina using an ASO targeting Cep290.

Methods : RNA-seq data were evaluated with proprietary transcriptome-independent approaches to identify annotated and novel non-productive splicing events. Cells were treated with various ASOs, and RNA/protein was extracted to verify RNA splicing effects and changes in protein expression. ASO targeting Cep290 was intravitreally injected in mice, and retinas were collected to evaluate ASO impact on splicing over time.

Results : Stoke has identified >100,000 non-productive splicing events amenable to our TANGO technology in >50% of genes. We developed ASOs targeting CD274 (PD-L1) that increase its mRNA and protein levels. We also demonstrate the ability to switch VEGF isoforms, functionally decreasing VEGF signaling. Finally, using a MOE-ASO targeting Cep290, we show that ASOs have activity in the mouse retina for >9 months following a single intravitreal injection.

Conclusions : Stoke’s technology offers an ASO-mediated strategy to increase target gene expression to treat a wide variety of diseases caused by haplo-insufficiency of a critical gene or by insufficient expression of specific pathway genes. We have demonstrated feasibility of this approach for treating ocular diseases. As over 50% of genes possess non-productive splicing events, the potential target opportunity is significant and largely untapped.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×